Clinical Trial Update: FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of FPI-2265 (225Ac-PSMA-I&T) and Olaparib for metastatic castration-resistant prostate cancer; the study is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• FPI-2265 (225Ac-PSMA-I&T) (225Ac-PSMA-I&T)
• Olaparib (Olaparib)

Snippet

Sponsor: Fusion Pharmaceuticals Inc. | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING